問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳信華

Recruiting

List

40Cases

2023-09-30 - 2026-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-12-14 - 2026-01-01

Phase III

A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients

  • Condition/Disease

    Gout

  • Test Drug

    Epaminurad

Participate Sites
13Sites

Not yet recruiting1Sites

Recruiting12Sites

2018-11-01 - 2022-04-30

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

方耀凡
Linkou Chang Gung Medical Foundation

Division of Rheumatology

2020-06-01 - 2022-01-31

Phase III

A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    Baricitinib

Participate Sites
9Sites

Recruiting9Sites

2024-09-01 - 2027-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2021-04-01 - 2024-05-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2022-10-13 - 2027-04-20

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2019-09-01 - 2022-12-17

Phase II

An adaptive Phase 2 randomized, double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of multiple LOU064 doses in patients with moderate to severe Sjögren’s Syndrome (LOUiSSe)

  • Condition/Disease

    Sjögren’s Syndrome

  • Test Drug

    LOU064

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

藍忠亮
China Medical University Hospital

2020-08-01 - 2023-06-26

Phase III

A two-year, phase III randomized, double-blind, parallel-group, placebocontrolled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis

  • Condition/Disease

    active lupus nephritis

  • Test Drug

    AIN457

Participate Sites
4Sites

Recruiting4Sites

2021-11-01 - 2023-03-02

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB